Internal Medicine Open Access, an official journal of OMICS International publishes all the articles related to Hemophilia. The journal is subjecting all the received manuscripts to a strict peer review process. The articles published in the journal are Open Access i.e, freely accessible to readers all around the world. Internal Medicine Open Access is maintaining the quality of articles through its strict peer review process.
Hemophilia is a group of genetic disorders that impairs blood clot formation. Hemophilia A is a deficiency in coagulation factor VIII (FVIII) and hemophilia B is a deficiency in coagulation factor IX (FIX). Current standard of care for hemophilia patients is protein replacement therapy whereby patients are intravenously infused with the missing coagulation factor and this is effective in limiting acute bleeds and reducing morbidity and mortality, as well as preventing long term disability, pain, and reduced range of motion in joints for both hemophilia A and B patients. However, the short half-life of FVIII and FIX require multiple weekly intravenous infusions to achieve hemostasis. This high frequency is inconvenient and costly and thus protein replacement therapy is often given in response to bleeds rather than prophylactically.
Last date updated on August, 2021